Jeet will be a trusted partner in cardiovascular care
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence
AI-driven company anumana partnered with Novartis to drive the development of its electrocardiogram (ECG) AI algorithms to detect subclinical heart disease.
The AICVD tool can predict the risk of cardiovascular disease.
The Cidmus brand shall be affixed on the pharmaceutical composition comprising a combination of Valsartan and Sacubitril (currently under Novartis patent) which is indicated for heart failure patients with reduced ejection fraction
New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease
Cardiovascular disease is the leading cause of death in the Asia Pacific, and it's a problem that will only intensify as populations continue to age
Subscribe To Our Newsletter & Stay Updated